Skip to main content
. 2020 Sep 30;2020:7603410. doi: 10.1155/2020/7603410

Figure 2.

Figure 2

(a) The HA of TCM plus entecavir versus entecavir. (b) The LN of TCM plus entecavir versus entecavir. (c) The PCIII of TCM plus entecavir versus entecavir. (d) The IV-C of TCM plus entecavir versus entecavir. I2 and P are the criterion for the heterogeneity test, ◆ pooled odds ratio, —■— odds ratio, and 95% CI.